Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer Meeting Abstract

  

Authors:	de Azambuja, E.; Saura, C.; Nuciforo, P.; Frantal, S.; Oliveira, M.; Zardavas, D.; Jallitsch-Halper, A.; de la Pena, L.; Dubsky, P.; Lombard, J. M.; Vuylsteke, P.; Altamirano, C. C.; Sanchez, C.; Ballestrero, A.; Colleoni, M.; Borges, G. S.; Ciruelos, E.; Bardia, A.; Fornier, M.; Boer, K.; Wilson, T. R.; Stout, T. J.; Hsu, J. Y.; Shi, Y.; Piccart, M.; Baselga, J.; Gnant, M.
Abstract Title:	Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer
Meeting Title:	40th Annual San Antonio Breast Cancer Symposium (SABCS 2017)
Journal Title:	Cancer Research
Volume:	78
Issue:	4 Suppl.
Meeting Dates:	2017 Dec 5-9
Meeting Location:	San Antonio, TX
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2018-02-01
Language:	English
ACCESSION:	WOS:000425489402265
PROVIDER:	wos
DOI:	10.1158/1538-7445.SABCS17-PD5-04
Notes:	Meeting Abstract: PD5-04 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/122654